Genentech Logo

Scientist Profile

Stephen Gould

Associate Director, Senior Scientist: Translational Oncology
Back to Scientist Profiles
 
"I am passionate about my work and believe that the ability to successfully bring drugs from paper to pill requires two basic elements: hard work and an environment that demands that the difficult questions be asked at each step of the process. Genentech provides an environment where this approach leads to amazing advances in the treatment of disease."
 

I joined Genentech in 2006 after seven years in the Boston biotech sector, four of which were spent in a productive collaboration with scientists here at Genentech. The decision to become an East Coast transplant was driven by my passion to take small molecule drugs from concept to patients, and to do so in an environment driven by science and the desire to have a dramatic impact on patient outcome.

As a transition point between the bench and the clinic, the translational oncology group is focused on providing data that determines the relative efficacy of new agents and correlates efficacy with target inhibition and drug exposures to help inform clinical strategy.

See More

 
 
My Focus

Currently, my laboratory supports several projects within the oncology pipeline including those aimed at targeting hedgehog and IAP pathways, as well as a number of projects targeting key signaling nodes downstream of cell surface tyrosine kinases. In addition, we continue to focus on identifying ways to improve the translational aspects of our work by gaining a more detailed understanding of pharmacokinetic and pharmacodynamic relationships for each of these targets. Such knowledge will enable more refined dose predictions in our clinical trials and ultimately lead to better decision-making and provide the right drug, at the right exposure, to our patients.

We have also turned our attention to the identification of potential mechanisms of resistance to our drugs so that we can proactively develop treatment strategies that will reduce the potential for resistance as well as to treat resistant tumors should they arise.

See More

 
Publications & Recognition
  • Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma..
  • Science 2009 Oct 23; 326(5952): 572-4
  • Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, Bazan JF, Kan Z, Seshagiri S, Hann CL, Gould SE, Low JA, Rudin CM, de Sauvage FJ.
  • View Abstract on PubMed
  • Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.
  • N Engl J Med 2009 Sep 17; 361(12): 1173-8.
  • Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, LoRusso PM, Von Hoff DD, de Sauvage FJ, Low JA.
  • View Abstract on PubMed
  • A paracrine requirement for hedgehog signalling in cancer.
  • Nature 2008 Sep 18; 455(7211): 406-10.
  • Yauch RL, Gould SE, Scales SJ, Tang T, Tian H, Ahn CP, Marshall D, Fu L, Januario T, Kallop D, Nannini-Pepe M, Kotkow K, Marsters JC, Rubin LL, de Sauvage FJ.
  • View Abstract on PubMed
 
View All Publications & Recognition
 
  • University of Connecticut Health Center, Department of Developmental Biology
  • Ph.D.
  • 1993
  • University of Massachusetts, North Dartmouth
  • B.S.
  • 1986
  • University of California, San Francisco, Department of Orthopedic Surgery
  • Postdoctoral Fellow
  • 1996-1998
  • University of Virginia, Department of Biology
  • Postdoctoral Fellow
  • 1993-1996
  • University of Connecticut Health Center, Department of Developmental Biology
  • Ph.D.
  • 1993
  • University of Massachusetts, North Dartmouth
  • B.S.
  • 1986
Publications & Recognition
  • Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.
  • Science 2009 Oct 23; 326(5952): 572-4.
  • Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, Bazan JF, Kan Z, Seshagiri S, Hann CL, Gould SE, Low JA, Rudin CM, de Sauvage FJ.
  • View Abstract on PubMed
  • Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.
  • N Engl J Med 2009 Sep 17; 361(12): 1173-8.
  • Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, LoRusso PM, Von Hoff DD, de Sauvage FJ, Low JA.
  • View Abstract on PubMed
  • A paracrine requirement for hedgehog signalling in cancer.
  • Nature 2008 Sep 18; 455(7211): 406-10.
  • Yauch RL, Gould SE, Scales SJ, Tang T, Tian H, Ahn CP, Marshall D, Fu L, Januario T, Kallop D, Nannini-Pepe M, Kotkow K, Marsters JC, Rubin LL, de Sauvage FJ.
  • View Abstract on PubMed
  • Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis.
  • Cell Stem Cell 2009 Jun 5; 4(6): 559-67.
  • Hofmann I, Stover EH, Cullen DE, Mao J, Morgan KJ, Lee BH, Kharas MG, Miller PG, Cornejo MG, Okabe R, Armstrong SA, Ghilardi N, Gould S, de Sauvage FJ, McMahon AP, Gilliland DG.
  • View Abstract on PubMed
  • Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice.
  • Cancer Cell 2004 Sep; 6(3): 229-40.s
  • Romer JT, Kimura H, Magdaleno S, Sasai K, Fuller C, Baines H, Connelly M, Stewart CF, Gould S, Rubin LL, Curran T.
  • View Abstract on PubMed
  • BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells.
  • Kidney Int 2002 Jan; 61(1): 51-60.
  • Gould SE, Day M, Jones SS, Dorai H.
  • View Abstract on PubMed
  • Cellular contribution of bone graft to fusion.
  • J Orthop Res 2000 Nov; 18(6): 920-7.
  • Gould SE, Rhee JM, Tay BK-B , Otsuka NY, Bradford DS.
  • View Abstract on PubMed
  • Histochemical and molecular analyses of distraction osteogenesis in a mouse model.
  • J Orthop Res 1998 Sep; 16(5): 636-42.
  • Tay BK, Le AX, Gould SE, Helms JA.
  • View Abstract on PubMed
  • Neural induction and antero-posterior patterning in the amphibian embryo: past, present and future..
  • Cell Mol Life Sci 1997 Apr; 53(4): 319-38
  • Gould SE, Grainger RM.
  • View Abstract on PubMed
  • Characterization of chicken syndecan-3 as a heparan sulfate proteoglycan and its expression during embryogenesis.
  • Dev Biol 1995 Apr; 168(2): 438-51.
  • Gould SE, Upholt WB, Kosher RA.
  • View Abstract on PubMed
  • Syndecan 3: a member of the syndecan family of membrane-intercalated proteoglycans that is expressed in high amounts at the onset of chicken limb cartilage differentiation.
  • Proc Natl Acad Sci U S A 1992 Apr 15; 89(8): 3271-5.
  • Gould SE, Upholt WB, Kosher RA.
  • View Abstract on PubMed
See More
Awards & Honors
  • New Investigator Award, Orthopedic Research Association--1998
  • American Cancer Society Postdoctoral Fellowship--1995-1998
  • Neural Behavior and Development Training Grant Postdoctoral Fellowship--1994-1995
  • Lepow Award for Outstanding Achievement, University of Connecticut Health Center--1992
  • Pre-doctoral Fellowship, University of Connecticut Health Center--1989-1991

Stephen Gould, Senior Scientist and Alex Avardo, Receipent of Free Medicine From the Genentech® Access to Care Foundation, on the cover of Genentech's 2006 Annual Report.